Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Deep Subgluteal Block vs PENG + LFCN Block for Hip Arthroplasty Pain

Official title: Comparison of Deep Subgluteal Block and Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia After Hip Arthroplasty: A Randomized Prospective Study

Run by Medipol University · NCT07770932 · Data updated 2026-11-12

This randomized study compares two ultrasound-guided nerve blocks to see which provides better pain control after hip replacement.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment60 (estimated)
SponsorMedipol University
Academic / other
Locations1 site (Istanbul, Bagcilar)
StatusRecruiting
StartedAugust 1, 2026
Main results expectedDecember 30, 2026
Study endsJanuary 30, 2027
Registry record updatedAugust 18, 2026
Trial IDNCT07770932 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 scheduled for elective hip arthroplasty under general anesthesia, ASA I–III, able to consent and use a PCA device.

Probably not a fit

Patients unlikely to benefit include those with contraindications to regional anesthesia or amide local anesthetic sensitivity, and those not meeting eligibility criteria.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this randomized, prospective, double-blind trial, 60 adults undergoing hip arthroplasty under general anesthesia are assigned to receive either a Deep Subgluteal Block or a Pericapsular Nerve Group block with a LFCN block, with all local anesthetic doses and volumes standardized. The primary outcome is total fentanyl use in the first 24 hours after surgery; secondary outcomes include pain scores at rest and with movement, quadriceps motor block, and opioid-related side effects. Procedures are performed postoperatively by an experienced anesthesiologist under ultrasound guidance to maintain blinding.

Why it matters

Potential benefit: If successful, the preferred block could reduce opioid needs and improve early postoperative pain control after hip arthroplasty.

How similar studies have gone: Previous regional anesthesia studies suggest block techniques can affect analgesia, but direct head-to-head comparison of DSGB versus PENG+LFCN for hip arthroplasty analgesia is not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients scheduled for elective total or partial hip arthroplasty under general anesthesia
* American Society of Anesthesiologists (ASA) physical status I-III
* Aged between 18 and 80 years
* Able to understand the study procedures, give voluntary written informed consent, and operate a patient-controlled analgesia (PCA) device

Exclusion Criteria:

* Patient refusal or inability to provide informed consent
* Pre-existing peripheral neuropathy, cognitive impairment, or psychiatric disorders
* History of significant severe renal or hepatic failure
* Allergy or hypersensitivity to amide-type local anesthetics or opioids
* Infection, severe anatomic distortion, or previous surgery at the proposed block injection sites
* History of substance abuse or chronic opioid use (defined as daily opioid use for \> 3 months prior to surgery)

Where it's running

  • Medipol Mega University Hospital
    Istanbul, Bagcilar, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.